ArriVent BioPharma, Inc. Common Stock
ArriVent BioPharma, Inc. Common Stock
Your view on AVBP
Overview
What the company does, where it operates, and who runs it.
About ArriVent BioPharma, Inc. Common Stock
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Zhengbin Yao
- Headquarters
- US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Zhengbin Yao
- Headquarters
- US
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.
It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002.
It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for ArriVent BioPharma, Inc. Common Stock, and the rating behind it. AVBP last traded at $29.00; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for ArriVent BioPharma, Inc. Common Stock. Starting points for ArriVent BioPharma, Inc. Common Stock: EPS -$3.44, beta 1.36 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for ArriVent BioPharma, Inc. Common Stock. ArriVent BioPharma, Inc. Common Stock does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for ArriVent BioPharma, Inc. Common Stock. Trailing twelve-month EPS for ArriVent BioPharma, Inc. Common Stock stands at -$3.44. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for ArriVent BioPharma, Inc. Common Stock. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
ArriVent BioPharma, Inc. Common Stock valued side by side against its closest peers. ArriVent BioPharma, Inc. Common Stock is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold ArriVent BioPharma, Inc. Common Stock, and how their positions are changing. At a $1.35B market value, institutional positions materially move ArriVent BioPharma, Inc. Common Stock's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by ArriVent BioPharma, Inc. Common Stock executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming ArriVent BioPharma, Inc. Common Stock. ArriVent BioPharma, Inc. Common Stock is a $1.35B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming ArriVent BioPharma, Inc. Common Stock. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for ArriVent BioPharma, Inc. Common Stock. Coverage tracks ArriVent BioPharma, Inc. Common Stock within Biotechnology (Healthcare). Press releases and market coverage, newest first.